Premarketing and Clinical Development Flashcards

A sponsor submits an Investigational New Drug (IND) application for a Phase 1 study. The FDA issues a clinical hold 25 days after submission. Which of the following is the MOST likely reason for the clinical hold?

Answer: The Investigator's Brochure is found to be misleading or materially incomplete.

According to FDA regulations (21 CFR 312.42), grounds for a clinical hold on a Phase 1 study include an Investigator's Brochure that is misleading, erroneous, or materially incomplete. Other primary reasons for a Phase 1 hold relate to unreasonable risk to subjects, unqualified investigators, or insufficient information to assess risk. Statistical power (A) is a concern for later phase studies, not typically Phase 1. Finalizing the commercial manufacturing process (C) is not required at the IND stage. The Phase 3 protocol (D) is not required for a Phase 1 study to commence.

A clinical investigator is preparing for a new industry-sponsored drug trial. By signing the Form FDA 1572, the investigator is making a legally binding commitment to the sponsor to perform which of the following actions?

Answer: Ensure the study is conducted according to the protocol and personally supervise the overall conduct of the trial.

The Form FDA 1572 is a Statement of Investigator, which serves as a signed agreement between the investigator and the sponsor. By signing it, the investigator commits to follow FDA regulations for conducting a clinical investigation. This includes personally conducting or supervising the study, ensuring it follows the approved protocol, and protecting the rights, safety, and welfare of subjects. It does not guarantee enrollment numbers (A), require the investigator to perform every single task without delegation (B), or involve them in the marketing approval process (D).

Which of the following is a required basic element of informed consent for a clinical trial, as specified in 21 CFR 50.25?

Answer: A disclosure of appropriate alternative procedures or courses of treatment, if any.

The FDA regulation 21 CFR 50.25 outlines the basic elements that must be included in an informed consent document. Among these is the requirement to disclose appropriate alternative procedures or treatments that might be advantageous to the subject. The IRB is not a government entity (A). While potential benefits are described, they cannot be guaranteed (B). The investigator's CV is not a required element of the consent form (C).

A medical device company plans to conduct a clinical study of a novel implantable cardiac defibrillator. The device is intended to sustain human life. According to 21 CFR 812, what is the regulatory status of this investigation and what is required before initiating the study?

Answer: Significant risk; both IRB approval and an approved Investigational Device Exemption (IDE) from the FDA are required.

An investigational device that is intended as an implant and presents a potential for serious risk, or is purported to be for use in supporting or sustaining human life, is considered a significant risk (SR) device. Clinical investigations of SR devices require both Institutional Review Board (IRB) approval and an approved Investigational Device Exemption (IDE) from the FDA before the study can begin.

A pharmaceutical company is developing a new drug for a serious condition with no available therapy. Preliminary clinical evidence suggests the drug may demonstrate a substantial improvement over existing standards of care on a clinically significant endpoint. Which expedited program would be MOST appropriate for the sponsor to request?

Answer: Breakthrough Therapy Designation

Breakthrough Therapy Designation is specifically for drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. While Fast Track also applies to serious conditions with unmet needs, the requirement for preliminary *clinical* evidence of *substantial improvement* is the key differentiator for Breakthrough Therapy. Accelerated Approval is an approval pathway based on a surrogate endpoint, and Priority Review shortens the FDA review clock but is requested at the time of NDA/BLA submission.

In the context of Good Clinical Practice (GCP), which of the following is a primary responsibility of a clinical trial investigator?

Answer: Protecting the rights, safety, and well-being of trial subjects.

A fundamental principle of Good Clinical Practice (GCP), as outlined in ICH E6, is that the investigator's primary responsibility is to protect the rights, safety, and well-being of the human subjects participating in a clinical trial. While other responsibilities like ensuring data integrity and protocol adherence are crucial, they all serve this primary duty. Commercial viability (A) is the sponsor's concern. Drafting the IND (B) is a sponsor responsibility. Ensuring fair compensation (C) is an element managed through the IRB-approved informed consent process, but the overarching responsibility is subject protection.